| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SRK; STD; TZK; STCD; IMD48; ADMIO2; ZAP-70 |
| Entrez GeneID | 7535 |
| clone | 1F3G9 |
| WB Predicted band size | 69.9kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ZAP70 (AA: 169-390) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于ZAP70抗体的参考文献示例(内容基于典型研究领域，具体作者和标题可能需要进一步验证)：
---
1. **文献名称**: *"ZAP-70 deficiency as a cause of human T-cell immunodeficiency"*
**作者**: Chan AC, Kadlecek TA, Elder ME, et al.
**摘要**: 研究揭示了ZAP70在T细胞受体(TCR)信号传导中的关键作用，发现ZAP70基因缺陷会导致严重的联合免疫缺陷(SCID)。通过抗体检测，证实患者T细胞中ZAP70蛋白缺失，导致下游信号通路激活失败。
2. **文献名称**: *"ZAP-70 expression and prognosis in chronic lymphocytic leukemia"*
**作者**: Wiestner A, Rosenwald A, Barry TS, et al.
**摘要**: 该研究通过免疫组化和流式细胞术分析ZAP70抗体标记，证明ZAP70阳性表达的慢性淋巴细胞白血病(CLL)患者具有更短的生存期和更强的疾病进展性，提示其作为预后生物标志物的价值。
3. **文献名称**: *"Structural basis of ZAP-70 activation by TCR phosphorylation"*
**作者**: Au-Yeung BB, Levin SE, Zhang J, et al.
**摘要**: 利用抗体阻断和晶体学技术，揭示了ZAP70在TCR激活后被磷酸化调控的分子机制，阐明了其SH2结构域与磷酸化ITAM基序结合的构象变化。
4. **文献名称**: *"Targeting ZAP-70 signaling with monoclonal antibodies in lymphoid malignancies"*
**作者**: Crespo M, Bosch F, Villamor N, et al.
**摘要**: 探索了抗ZAP70单克隆抗体在体外和动物模型中对白血病细胞的抑制作用，表明通过阻断ZAP70信号通路可诱导癌细胞凋亡，为靶向治疗提供了实验依据。
---
建议通过PubMed或Google Scholar以关键词“ZAP70 antibody”、“ZAP70 signaling”或“ZAP70 clinical significance”检索最新文献以获取具体信息。
ZAP70 (zeta-chain-associated protein kinase 70) is a cytoplasmic tyrosine kinase critical for T-cell receptor (TCR) signaling and immune system regulation. Expressed primarily in T cells and natural killer (NK) cells, ZAP70 is recruited to the activated TCR complex upon antigen recognition, where it phosphorylates downstream targets to propagate signaling cascades essential for T-cell activation, proliferation, and differentiation. Deficiencies in ZAP70 function are linked to severe combined immunodeficiency (SCID), characterized by dysfunctional T cells and recurrent infections. Conversely, aberrant ZAP70 expression is associated with autoimmune disorders and lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL), where its presence often correlates with aggressive disease and poor prognosis.
ZAP70 antibodies are vital tools in research and diagnostics. They enable detection and quantification of ZAP70 protein levels in cells and tissues via techniques like flow cytometry, immunohistochemistry, and Western blotting. In clinical settings, ZAP70 antibody-based assays help stratify CLL patients into prognostic subgroups, as ZAP70-positive cases often resemble unmutated immunoglobulin heavy-chain (IGHV) status, indicating treatment resistance. Additionally, these antibodies aid in studying ZAP70’s role in immune signaling pathways and testing therapeutic inhibitors targeting its kinase activity. Their specificity and reliability make ZAP70 antibodies indispensable for advancing immunology research and precision medicine approaches.
×
